Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Attached to lymphokine – cytokine – or other secreted growth...
Reexamination Certificate
2003-05-21
2008-03-18
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Attached to lymphokine, cytokine, or other secreted growth...
C424S009341, C424S085100, C514S008100, C514S021800, C530S351000
Reexamination Certificate
active
07344699
ABSTRACT:
A drug conjugate comprising a targeting agent and an anti-cancer agent, wherein said targeting agent comprises an erythropoietin receptor ligand, is described. The drug conjugate can be used in methods of treating cancer. Also described are methods of treating cancer using the conjugate, methods of diagnosis, methods of imaging and pharmaceutical compositions.
REFERENCES:
patent: 6221608 (2001-04-01), Johnson et al.
patent: WO 98/10650 (1998-03-01), None
patent: WO 00/61164 (2000-10-01), None
patent: WO 00/67769 (2000-11-01), None
Haroon et al. Functional significance of erythropoietin receptor expression in breast cancer. Blood. Nov. 16, 2001, vol. 98 (11 Part 1), pp. 300a-301a.
Kayser et al. Analysis of expression of erythropoietin-binding sites in human lung carcinoma by the biotinylated ligand. Zentralblatt fur Pathologie. Sep. 1992, vol. 138, No. 4, pp. 266-270.
Wognum et al. Increased Erythropoietin-Receptor Expression . . . Blood. Feb. 1, 1992, vol. 79, No. 3, pp. 642-649.
Kratz, et al.; “Synthesis of new maleimide derivatives of daunorubicin and biological activity of acid labile transferring conjugates”; Bioorganic & Medicinal Chemistry Letters, Oxford, GB; Mar. 4, 1997; vol. 7, No. 5, pp. 617-622.
Roodman, et al.; “DNA polymerase activities during erythropoiesis. Effect of erythropietin, vinblastine, colcemid, and daunomycin.”; Experimental Cell Research; Mar. 15, 1975; vol. 91, No. 2, pp. 269-278.
Lappin Terence
Mann John
Maxwell Perry
McManus Michael
DLA Piper (US) LLP
Russel Jeffrey Edwin
The Queen's University of Belfast
LandOfFree
Drug conjugate comprising an erythropoietin receptor ligand... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Drug conjugate comprising an erythropoietin receptor ligand..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drug conjugate comprising an erythropoietin receptor ligand... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3963292